Avidity Biosciences Inc
RNAM
Rangering i aksjer
#2069
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Aksjekurs
$71.34
Sist synkronisert: 2026-03-03
Markedsverdi
$9.84B
Endring (1 dag)
0.00%
Endring (1 år)
-
Land
US
Handel Avidity Biosciences Inc (RNAM)
Kategori
Healthcare
P/B-forhold for Avidity Biosciences Inc (RNAM)
P/B-forhold per October 2026 TTM: 6.44
Ifølge Avidity Biosciences Inc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 6.44. Ved slutten av 2024 hadde selskapet et P/B-forhold på 5.69.
P/B-historikk for Avidity Biosciences Inc fra 2018 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.44 | 8.80% |
| 2025 | 5.92 | 4.15% |
| 2024 | 5.69 | -46.29% |
| 2023 | 10.59 | 61.58% |
| 2022 | 6.55 | -16.92% |
| 2021 | 7.89 | 53.53% |
| 2020 | 5.14 | -112.32% |
| 2019 | -41.71 | -37.04% |
| 2018 | -66.25 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.6964 | 3.97% |
US
|
|
| 13.6307 | 111.63% |
US
|
|
| 4.4521 | -30.88% |
AU
|
|
| 4.2241 | -34.42% |
BE
|
|
| 6.3632 | -1.21% |
NL
|
